After extremely weak performance in early 2014, the biotechnology industry understandably dropped off the radar of most investors. For those who haven’t been watching, the industry has quietly been making a comeback. For risk-tolerant investors, now could be the time to give it a second look. (For more, see: The Ups and Downs of Biotechnology.)

As you can see from the chart of the SPDR S&P Biotech Index ETF (XBI), the sector has been trading within an extremely strong uptrend since 2010. This year’s extremely wide range of $171.47 in February to the low of $118 in April is a clear example of the type of volatility that traders in this industry can expect so proceed with caution. (For more, see: The Industry Handbook: Biotechnology.)

Biotech Investing Risks

Investing in biotechnology comes with a host of risks. In most cases, these companies can live or die based on results of drug trials. As investors in Dendreon Corp. (DNDN) are painfully aware, one day you can be on top of the world, and the next you can see your investment halved — or worse. The 10-year weekly chart (below) is a clear example of how important timing can be. Investment experience, risk tolerance and capital protection are key when it comes to investing in biotechnology, and it can be extremely costly for those who venture in unaware of the risk. (For more, see: A Primer on the Biotech Sector.)

Key Players In Biotechnology

Traders who want to invest in biotech companies directly but don’t know where to start should consider checking out the top holdings of the SPDR S&P Biotech ETF. The top-five holdings are shown in the table below:


Weighting (%)

Puma Biotechnology Inc. (PBYI)


InterMune Inc. (ITMN)


Anacor Pharmaceuticals Inc. (ANAC)


Exact Sciences Corp. (EXAS)


Gilead Sciences Inc. (GILD)



As discussed above, biotech companies generally live or die based on trial results. There is no better example of this so far in 2014 than Puma Biotechnology, which shot up 295% on July 23 when the company announced news from a Phase III trial of its experimental breast cancer drug. This type of move can turn investors such as Alan Auerbach, the company’s founder, into a billionaire overnight. It's the type of move that most biotech investors dream of but is the exception rather than the rule. The question now for most investors is whether the company is now positioned for a buyout, which would send the stock even higher. (For related reading, see: 8 Stages of New Drug Development.)

The Bottom Line

When it comes to investing in biotechnology, it's important to understand the risk. Granted, there are few industries in which companies can go from relatively unknowns to billion-dollar enterprises overnight. This definitely has its allure, but remember that fortunes can be made and lost in a blink so be sure to tread carefully. For those who want to gain exposure to the sector, one popular tool could be the XBI ETF. For those who want to invest in specific biotechs, it may be wise to check out the components of the ETF for ideas. (For more, see: Investing In The Biotech Sector and How Gilead Became A Big Name In Biotech.)

Related Articles
  1. Stock Analysis

    How Gilead Sciences Became A Big Name In Biotech

    How does a company start with an unfortunate bout of dengue fever and grow to be a multibillion dollar corporation?
  2. Economics

    India: Why it Might Pay to Be Bullish Right Now

    Many investors are bullish on India for all the right reasons. Does it present an investing opportunity?
  3. Products and Investments

    There's a Reason They're Called Junk Bonds

    The closing of Third Avenue Managemet's Focused Credit Fund is a warning to investors and advisors. Beware the junk.
  4. Mutual Funds & ETFs

    Top 3 PIMCO Funds for Retirement Diversification in 2016

    Explore analyses of the top three PIMCO funds for 2016 and learn how these funds can be used to create a diversified retirement portfolio.
  5. Stock Analysis

    Forest Laboratories: An Activist Investment Analysis

    Find out how patience and perseverance paid off big-time for billionaire activist Carl Icahn during his four-year fight with Forest Laboratories.
  6. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  7. Stock Analysis

    Moderna Therapeutics: An IPO Candidate in 2016?

    Find out the reasons why 2016 may be the year when highly valued biotech company Moderna Therapeutic files for an initial public offering (IPO).
  8. Investing News

    Zika: Study Says This Device Could Protect You

    New research just uncovered an inexpensive, commercially available device that might help fight off the mosquito that carries the dreaded Zika virus.
  9. Mutual Funds & ETFs

    The 5 Best T. Rowe Price Funds for the Income Seeker in 2016 (TROW)

    Find out which T. Rowe Price mutual funds to use to create a diversified income portfolio for current income, income growth and capital preservation.
  10. Investing Basics

    Building My Portfolio with BlackRock ETFs and Mutual Funds (ITOT, IXUS)

    Find out how to construct the ideal investment portfolio utilizing BlackRock's tools, resources and its popular low-cost exchange-traded funds (ETFs).
  1. What's the difference between a stop and a limit order?

    Different types of orders allow you to be more specific about how you'd like your broker to fulfill your trades. When you ... Read Full Answer >>
  2. Are secured personal loans better than unsecured loans?

    Secured loans are better for the borrower than unsecured loans because the loan terms are more agreeable. Often, the interest ... Read Full Answer >>
  3. Which mutual funds made money in 2008?

    Out of the 2,800 mutual funds that Morningstar, Inc., the leading provider of independent investment research in North America, ... Read Full Answer >>
  4. Should mutual funds be subject to more regulation?

    Mutual funds, when compared to other types of pooled investments such as hedge funds, have very strict regulations. In fact, ... Read Full Answer >>
  5. Do ETFs pay capital gains?

    Exchange-traded funds (ETFs) can generate capital gains that are transferred to shareholders, typically once a year, triggering ... Read Full Answer >>
  6. How do real estate hedge funds work?

    A hedge fund is a type of investment vehicle and business structure that aggregates capital from multiple investors and invests ... Read Full Answer >>
Trading Center